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Abstract: Introduction: The global prevalence of type 2 diabetes (T2D) is increasing rapidly, especially
in low- and middle-income countries and has a high number of associated comorbidities. Plasmatic
concentrations of branched chain amino acids (BCAA) and retinol-binding protein 4 (RBP4) have
been shown to be elevated in T2D subjects in cross-sectional studies. However, the effect of lifestyle
community-based interventions on BCAA and RBP4 concentrations has not yet been analyzed.
Material and methods: The Feel4Diabetes study is a school and community-based intervention that
identified 360 European families with a high risk of developing T2D according to the FINDRISC
questionnaire. Families were randomized in control and intervention groups were followed-up from
2016 to 2018. In the Spanish families, the concentration of BCAA and RBP4 was determined in
266 subjects (115 control and 151 intervention group) that attended the three time-point assessments
by colorimetric and ELISA reaction, respectively. Results: Baseline BCAA levels showed positive
correlations with the FINDRISC score and glucose impairment (baseline glucose, insulin, and glycated
hemoglobin), body mass index, and body weight. The participants receiving the community-based
intervention showed a significant decrease in glycated hemoglobin and BCAA levels compared to
the control group (p = 0.011 and p < 0.001, respectively). However, baseline RBP4 did not show
significant correlations with anthropometric and glycemic parameters, and no significant change
was observed in anthropometric parameters and RBP4 concentrations throughout the follow-up.
Conclusion: A community-based intervention on lifestyle led to a significant reduction in BCAA
levels regardless of weight loss. These findings suggest that this interventional approach could be
promising in T2D prevention.
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1. Introduction
Type 2 diabetes (T2D) doubles the risk of cardiovascular disease mortality and it is associated
with increased morbimortality risk from numerous other causes and reduced quality of life [1,2]. The
global prevalence of T2D is increasing rapidly, especially in low- and middle-income countries, which
is mainly attributable to environmental and behavioral risk factors [3,4]. Finding lifestyle intervention
strategies that are effective at preventing or delaying the onset of T2D and early identification of those
individuals at high risk constitute a priority for the scientific community [5].
Metabolomics have recently found biochemical changes that occur before T2D onset and can
elucidate its pathophysiology to facilitate new approaches to prevention and management [6,7].
Branched-chain amino acids (BCAA) have been identified as potential contributors to glucose
impairment, insulin resistance, and increased T2D incidence risk, although the responsible mechanisms
for these effects are not fully understood [8–10]. It has been demonstrated that intracellular accumulation
of BCAA activates the mammalian target of rapamycin (mTOR), resulting in insulin signaling
inhibition [10,11]. Recently, brown adipose tissue has been founded to have an essential role in BCAA
clearance [12]. Thus, impaired brown adipose tissue activity in conditions such as obesity or T2D
decreases systemic BCAA clearance. Adipose tissue dysfunction is characterized by hypertrophy,
increased autophagy and apoptosis, and inflammatory processes, among others [13]. Adipocytes
release adipokines, whose circulating levels reflect adipose tissue impairment and are directly linked
to cardiometabolic diseases. Retinol-binding protein 4 (RBP4) is a recently recognized adipokine, and
several epidemiological studies have demonstrated that elevated serum RBP4 concentrations play a
critical role in the development of insulin resistance and T2D [14,15]. Among adipokines, RBP4 is the
one most related to glycemic homeostasis and other cardiometabolic parameters (like triglycerides)
regardless of weight loss. However, the effect of lifestyle interventions in studies with a large sample
size has barely been explored. Besides, other previous studies have demonstrated that RBP4 levels
seem to be quite modifiable by style–life modification, decreasing with hyper protein hypocaloric diets
and directly associated with triglyceride concentration improvement [16]. Most of the studies exploring
the association between BCAA and RBP4 with glucose metabolism impairment are observational and
they have been carried out in subjects with prediabetes or T2D. However, while subjects with high
risk of developing T2D have elevated levels of BCAA and RBP4; whether they are related to glucose
homeostasis and lifestyle intervention which could impact their concentrations has not been previously
explored and could be useful to find early markers of disease onset. Thus, the aim of this study is to
explore the circulating levels of BCAA and RBP4 in adult subjects with high risk of developing T2D,
based on a validated questionnaire (Finnish Diabetes Risk Score, FINDRISC), to find if they are related
to glucose parameters and if a community-based lifestyle intervention has a significant impact on
their concentrations.
2. Material and Methods
2.1. Study Population and Design
The current study has been developed to include Spanish participant data from the
Feel4Diabetes-study, which is an EU-funded study aimed at carrying out, implementing, and evaluating
school- and community-based interventions to prevent T2D in families from vulnerable population
groups across Europe. The Feel4Diabetes-study is registered at clinicaltrials.gov as NCT02393872, and
further information about it can be found at the following website: http://feel4diabetes-study.eu/.
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The methodology of the study has been previously explained in depth [17]. Briefly, the study
recruited participants from vulnerable population-groups in six European countries, including Bulgaria,
Hungary, Belgium, Finland, Greece, and Spain. Those families within schools from municipalities with
the lowest educational levels or the highest unemployment rates were considered as vulnerable groups
and were recruited in the city of Zaragoza (Spain). Participants at high risk of developing T2D were
identified through the FINDRISC questionnaire [17]. Previous studies have demonstrated that the
FINDRISC questionnaire has good validity for identifying subjects at increased risk of T2D and is the
most used diabetes risk score in Europe [18–20]. In this study, families were contacted at schools and
those participants with a FINDRISC score ≥9 were considered as high risk. Families with at least one
member at high risk based on FINDRISC were considered as “high risk families”. The randomization
to the intervention and control groups was performed at a municipality level (1:1 ratio) after baseline
measurements were completed. Thus, the schools and the families (both all families and “high risk
families”) within each municipality were automatically allocated to the intervention or control group.
“High risk” participants had follow-ups at the Hospital Universitario Miguel Servet where clinical,
anthropometric, and biochemical parameters were collected at baseline (2016), after one year of the
follow-up (Follow-up 1, 2017) and after two years of the follow-up (Follow-up 2, 2018).
Lifestyle intervention was implemented from 2016 to 2018, which has already been explained
in detail elsewhere [17]. It has two different components: (1) the “all families” component, which
was developed at schools, home, and the local municipalities; (2) “high risk families”, which was
delivered out of the school setting for just these families. For example, the “all families” component
involved activities at school aiming to increase water consumption (instead of sugary drinks) or to
increase the intake of fruits and vegetables, among others. Furthermore, changes in infrastructure
and human resources at the municipality level were promoted to facilitate healthy lifestyle adherence
and behavioral changes of families. The “high risk families” component included seven lifestyle
counseling sessions spread over the academic years 2016–2017 that were focused on (a) decreasing
body weight by 5% (if there were overweight or obese participants); (b) increasing the consumption of
whole grains, nuts, low-fat dairy, and olive and rapeseed oils; and (c) decreasing the intake of snacks,
fast foods, red and processed meat. The seventh session consisted of an individual visit of the high-risk
participant who underwent the clinical visit by including medical check-up discussions and setting
specific and feasible goals within every lifestyle change. High risk participants in the control group
also received this personal session, which consisted of a medical check-up explanation and general
healthy lifestyle counseling. “High risk families” received motivational messages on their mobile
phones during the second year of the study (2017) with the objective of reaching the healthy lifestyle
goals previously stated.
2.2. Anthropometric, Clinical, and Biochemical Parameters
These parameters were collected in high risk participants both in the control and intervention
groups at baseline, Follow-up 1, and Follow-up 2. Bodyweight was measured twice without shoes
with a calibrated scale (Seca 813, Seca Deutschland®, Hamburg, Deutschland, Germany). If the
difference between the two measurements was greater than 0.1 kg, a third assessment was performed.
Height was assessed twice with a wall-mounted stadiometer (Seca 217, Seca Deutschland®, Hamburg,
Deutschland, Germany). If the difference between the two measurements was greater than 0.1 cm, a
third assessment was carried out. BMI was calculated as weight in kilograms divided by the square of
height in meters. Blood pressure was measured in triplicate with a validated semiautomatic oscillometer
(Omron M3, Omron Cop; Hoofdorp, the Netherlands). All measurements were taken in accordance
with the recommended guidelines: no food or drink 3 h prior to measurements, no exhausting exercise
12 h prior to measurements, and no alcohol or caffeine consumption 24 h prior to measurements. We
calculated the mean of two or three measurements, if applicable, for these parameters.
Blood samples were drawn by venipuncture after at least 10 hours of overnight fasting. The levels
of total cholesterol (TC), triglycerides (TG), and HDL cholesterol (HDLc), uric acid, gamma-glutamyl
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transferase (GGT), glutamic-pyruvic transaminase (GPT), and aspartate transaminase (AST) were
determined by standard enzymatic methods. LDL cholesterol levels were calculated with the
Friedewald’s formula when serum TG was <400 mg/dL. Non-HDLc was calculated as total cholesterol
minus HDLc. Blood glucose concentration was measured with the glucose-oxidase method. Insulin
levels were measured via radioimmunoassay and homeostasis model assessment of insulin resistance
(HOMA–IR) and were estimated as fasting serum glucose (mg/dL) × plasma insulin (µU/mL)/405.
Glycated hemoglobin (HbA1c) was determined via high-performance liquid chromatography.
2.3. Dietary and Physical Parameters
To evaluate the impact of the Feel4Diabetes-intervention, the participants completed standardized
questionnaires, including information about drinking, eating, physical activity, and sedentary habits.
Based on the frequency and quantity of food consumption, we calculated the intake of each food group
per week. Physical activity was monitored by pedometers or accelerometers [17].
2.4. Branched Amino Acid and Retinol-Binding Protein 4 Quantification
Serum samples were stored at −80 ◦C until assayed. Serum BCAA (isoleucine, leucine, and valine)
were quantified using a branched amino acid kit (MAK003, Sigma-Aldrich, Merck Life Science S.L.U,
Madrid, Spain). Serum RBP4 was quantified with the RayBio®Human RBP-4 ELISA kit (RayBiotech,
Inc, Peachtree Corners, GA, USA). Both analyses were performed in duplicates, and serum sample
dilutions were done according to the detection range of each. Briefly, serum BCAA was determined
by adding 13 µL of serum sample with 37 BCAA assay buffer and 50 µL of assay reaction. Leucine
standard was prepared from 10 µL of leucine 10 mM with 90 µL of BCAA assay buffer. All samples
were incubated for 30 min at room temperature protected from light, immediately the absorbance
was measured at 450 nm on SYNERGY HT (BioTek, Instruments, Inc, Winooski, VT, USA) and data
was collected and analyzed using GEN5TM software (BioTek, Instruments, Inc, Winooski, VT, USA).
RBP4 serum was determined by adding 100 µL of RBP4 standard or dilution samples in the plate
incubating the samples for 2 hours and 30 min at room temperature in an orbital plate shaker. Dilution
samples and RPB4 standard were decanted, and 100 µL of diluted antibody was added in each well,
incubating the mix for one hour at room temperature in an orbital plate shaker. After that, the mix
was decanted and 100 µL of diluted streptavidin was added in each well, incubating the mix for 45
min at room temperature in an orbital plate shaker. Then, after decanting the mix again, 100 µL of
TMB-One Step was added, incubating the mix for 30 min at room temperature in an orbital plate
shaker protected from light. Finally, 50 µL of STOP solution was added to each well; immediately, the
absorbance was measured at 450 nm on a SYNERGY HT (BioTek, Instruments, Inc, Winooski, VT, USA)
and data was collected and analyzed using GEN5TM software (BioTek, Instruments, Inc, Winooski, VT,
USA). Intra and inter-assay coefficients of variation of ELISA assays were less than 10% and less than
12%, respectively.
2.5. Statistical Analysis
Continuous variables are expressed as mean ± SD or median (25th–75th percentile), according to
their distribution. Categorical variables are reported as n (percentages). ANOVA and Kruskal–Wallis
tests were performed for the comparison of multiple independent variables. Categorical variables
were compared using the chi-squared test by including inter-group comparison. Pearson’s tests of
correlation were applied as appropriate. Differences in paired variables were calculated with the
dependent t-test for paired samples or with the Wilcoxon test, as applicable. To assess differences
in RBP4 and BCAA concentrations among groups, the effect of the lifestyle intervention on different
cardiometabolic parameter changes and the impact of RBP4 and BCAA in this association, we applied
multiple linear regression while including weight loss and sex as independent variables. All statistical
analyses were performed with R software (version 3.5.0) and significance was set at p < 0.05 [21].
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3. Results
3.1. Baseline and Anthropometric Characteristics
Out of 487 participants who attended the first year (2016), 266 subjects attended the three study
visits, and they were included in the current study. Of the 266 subjects, 115 (43.2%) belonged to
the control group, while 151 (56.8%) belonged to the intervention group (Figure S1). As shown in
Table 1, those participants allocated to the intervention group had significantly higher levels of baseline
insulin and HOMA–IR than those in the control group (p = 0.027 and p = 0.045, respectively). The
participants randomized to either the intervention or control groups did not differ in any other clinical,
anthropometric, or biochemical characteristics at baseline. Importantly, there were no significant
differences in baseline concentrations of BCAA and RBP4 between both groups (p = 0.745 and p = 0.327,
respectively; Table 1).
Table 1. Baseline biochemical and anthropometric characteristics of all Spanish subjects who have
completed the Feel4Diabetes study.
Control Group
(N = 115)
Intervention Group
(N = 151) p
Age, years 42.5 ± 5.13 42.0 ± 5.26 0.483
Men, n (%) 39 (33.9%) 51 (33.5%) 0.682
Baseline body weight, kg 78.7 ± 17.5 80.1 ± 17.1 0.508
Baseline BMI, kg/m2 28.5 ± 5.75 28.9 ± 5.20 0.502
Baseline waist, cm 96.4 ± 13.3 98.1 ± 12.8 0.293
Baseline total cholesterol, mg/dL 202 ± 34.6 198 ± 34.6 0.326
Baseline LDL cholesterol, mg/dL 127 ± 29.7 124 ± 29.4 0.365
Baseline triglycerides, mg/dL 88.0 (31.0–118) 80.0 (63.0–119) 0.499
Baseline HDL cholesterol, mg/dL 54.6 ± 12.7 53.7 ± 11.1 0.550
Baseline apolipoprotein A, mg/dL 169 ± 32.5 167 ± 24.6 0.642
Baseline apolipoprotein B, mg/dL 96.9 ± 23.9 95.9 ± 25.9 0.583
Baseline glucose, mg/dL 92.4 ± 18.1 91.9 ± 15.4 0.621
Baseline insulin, UI 6.04 ± 3.68 7.21 ± 4.81 0.027
Baseline HbA1c, % 5.53 ± 0.75 5.51 ± 0.44 0.569
Baseline HOMA-IR 1.35 ± 0.85 1.68 ± 1.30 0.045
Baseline GGT, U/L 27.3± 20.5 27.1 ± 26.1 0.722
Baseline GOT, U/L 20.8± 7.63 21.3 ± 6.60 0.211
Baseline GPT, U/L 22.0 ± 14.9 20.3 ± 11.5 0.737
Baseline DM, n (%) Prediabetes
1 10 (8.69%) 12 (7.95%)
0.776Diabetes 2 4 (3.48%) 8 (5.26%)
Baseline score FINDRISK 12.0 (10.0–13.0) 11.0 (9.50–13.0) 0.224
Baseline BCAA, nmol/nL 406 ± 105 411 ± 113 0.745
Baseline RBP4, ng/ml 7.09 ± 5.18 7.57 ± 5.12 0.327
Physical activity, steps/day 6071 ± 3387 7082 ± 2756 0.364
BMI: body mass index. LDL: low density lipoprotein. HDL: high density lipoprotein. HOMA: homeostatic
model assessment. GGT: gamma-glutamyl transferase. GOT: glutamic oxaloacetic transaminase. GPT:
glutamic-pyruvate-transaminase. HbA1c: glycated hemoglobin. BCAA: branched amino acid. RBP4: retinol-binding
protein 4. Physical activity was measured as the total steps per day. Quantitative variables are expressed as
means ± standard deviations, except for variables not following normal distribution that are expressed as medians
(interquartile ranges). Qualitative variables are expressed as percentages. The p-value was calculated by t-test or U
Mann–Whitney and chi-square, as appropriate. 1 We defined prediabetes: subjects with baseline glucose levels >100
and <126 mg/dL and HbA1c between >5.7% and <6.5%. 2 We defined diabetes: subjects with baseline glucose levels
≥126 mg/dL and/or HbA1c ≥6.5%.
Table 2 shows baseline clinical, anthropometric, and biochemical characteristics and baseline
BCAA and RBP4 concentrations of participants based on the presence of impaired glycemic metabolism.
There was a higher prevalence of men in diabetic and prediabetic groups compared to normoglycemic
groups (p = 0.004). Diabetic and prediabetic subjects had significantly higher baseline body weight,
BMI, and TG concentration than control groups, which was especially remarkable in diabetic subjects.
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We observed expected differences among groups in glycemic metabolism (p = 0.043, p = 0.045 and
p = 0.020, respectively). Interestingly, BCAA showed a direct association with impaired glycemic
metabolism by founding significantly higher concentration in prediabetic and especially in diabetic
subjects than in the control group (p = 0.018). However, baseline concentrations of RBP4 have not
shown any relationship with impaired glycemic metabolism (p = 0.192). Besides, we found that there
was not a significant difference between BCAA or RBP4 levels according to diabetic therapy (oral
antidiabetic vs. insulin therapy).
Table 2. Baseline biochemical and anthropometric characteristics and baseline BCAAs and RBP4
concentrations according to impaired glycemic metabolism.
Diabetic Subjects 1
(N = 12)
Prediabetic Subjects 2
(N = 22)
Normoglycemic Subjects
(N = 232) p
Age, years 43.5 ± 3.02 43.8 ± 5.23 42.0 ± 5.27 0.237
Men, n (%) 7 (58.3%) 13 (59.1%) 70 (30.2%) 0.004
Baseline body weight, kg 89.9 ± 20.8 83.6 ± 15.2 78.6 ± 17.1 0.043
Baseline BMI, kg/m2 32.1 ± 7.02 30.0 ± 4.37 28.5 ± 5.39 0.045
Baseline waist, cm 106 ± 19.4 100 ± 8.62 96.8 ± 12.9 0.062
Baseline total cholesterol,
mg/dL 196 ± 41.3 210 ± 35.5 199 ± 34.1 0.357
Baseline LDL cholesterol,
mg/dL 113 ± 32.6 133 ± 28.8 125 ± 29.4 0.183
Baseline triglycerides, mg/dL 126 (109–187) 87.5 (70.5–169) 81.0 (62.0–111) 0.020
Baseline HDL cholesterol,
mg/dL 49.4 ± 10.9 53.5 ± 9.62 54.4 ± 12.0 0.356
Baseline glucose, mg/dL 146 ± 43.1 106 ± 5.19 88.1 ± 6.44 <0.001
Baseline insulin, UI 10.1 ± 7.09 7.49 ± 3.90 6.52 ± 4.29 0.104
Baseline HbA1c, % 7.24 ± 1.76 5.70 ±0.24 5.41 ± 0.29 <0.001
Baseline HOMA-IR 3.15 ± 2.48 2.00 ± 1.16 1.44 ± 1.02 0.001
Baseline BCAA, nmol/nL 486 ± 114 435 ± 69.3 403 ± 111 0.018
Baseline RBP4, ng/ml 7.92 ± 3.55 8.24 ± 3.99 7.25 ± 5.31 0.192
Physical activity, steps/day 4291 ± 1293 6990 ± 3114 6930 ± 2947 0.466
BMI: body mass index. LDL: Low density lipoprotein. HDL: high density lipoprotein. HOMA: homeostatic
model assessment. HbA1c: glycated hemoglobin. BCAA: branched amino acid. RBP4: retinol-binding protein
4. Physical activity was measured as the total steps per day. Quantitative variables are expressed as means ±
standard deviations; qualitative variables are expressed as percentages. The p-value was calculated by ANOVA test
or Kruskall–Wallis and chi-square, as appropriate. 1 We defined prediabetes: subjects with baseline glucose levels
>100 and <126 mg/dL and HbA1c between >5.7% and <6.5%. 2 We defined diabetes: subjects with baseline glucose
levels ≥126 mg/dL and/or HbA1c ≥6.5%.
3.2. Relationship between BCAA and RBP4 with Clinical, Anthropometrics, Glucose Metabolism, Lifestyle and
T2D Risk at Baseline
Baseline BCAA displayed a significant correlation with sex, showing BCAA concentrations were
significantly higher in men than women and this difference was maintained throughout the follow-up
regardless of whether they belonged to the control or intervention group (p < 0.001, Figure S2). Baseline
BCAA levels showed a significant positive correlation with anthropometric parameters like baseline
body weight and BMI (r = 0.30, p < 0.001 and r = 0.20, p < 0.001 respectively), and a positive correlation
with glycemic markers like glucose, Hb1Ac, insulin, and HOMA-IR (r = 0.20, p < 0.001; r = 0.20,
p < 0.001; r = 0.40, p < 0.001; and r = 0.40, p < 0.001, respectively; Figure 1A). However, baseline
RBP4 concentrations have not showed any correlation with anthropometrics and glucose metabolism
parameters (Figure 1B). Baseline BCAA levels had a significant positive correlation with legumes, red
meat, and soft drinks consumption (r = 0.20, p < 0.001; r = 0.10, p = 0.019; and r = 0.20, p = 0.009
respectively) and a significant negative correlation to vegetable intake (r = −0.20, p = 0.006; Figure 2A).
Nevertheless, baseline RBP4 concentrations did not show any correlation with legumes, red meat,
soft drinks, and vegetables consumption, although its concentration had a significant and positive
correlation to fish consumption (r = 0.20, p < 0.001; Figure 2B). Baseline BCAA showed significant
positive correlation with baseline gamma glutamyl transferase, transaminase glutamic pyruvic, and
systolic blood pressure (r = 0.20, p < 0.001; r = 0.20, p = 0.002; r = 0.20, p < 0.001, respectively) and
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significant negative correlation with HDLc (r = 0.20, p < 0.001, Figure S3A). Baseline RBP4 showed
significant positive correlation with baseline TG and diastolic blood pressure (r = 0.20, p = 0.013;
r = 0.20, p < 0.001, respectively; Figure S3B).
Figure 1. Correlation between baseline levels of BCAA (A) or RBP4 (B) with anthropometric and
diabetes markers (N = 266). BCAAs: branched amino acids; BMI: body mass index; HbA1c: glycated
hemoglobin; HOMA: homeostatic model assessment. Correlation analyzed was performed by Pearson’s
tests. * Denotes significant difference with p < 0.05.
Figure 2. Correlation between baseline dietary items and baseline BCAA (A) or RBP4 (B) levels
(N = 266). BCAA: branched amino acid. Correlation analyzed was performed by Pearson’s tests.
* Denotes significant difference with p < 0.05.
Finally, we analyzed the relationship between baseline BCAA and RBP4 levels and the FINDRISC
score, which assessed T2D risk. Baseline FINDRISC score showed significant association with baseline
BCAA quartiles, indicating that participants with higher values of FINDRISC score were also those
with higher baseline BCAA concentrations (p = 0.039, Figure 3). However, baseline FINDRISC scores
did not show any relation with baseline RBP4 concentrations (p = 0.943, Figure 3). When we analyzed
the FINDRISC score, according to the items questionnaire, only FINDRISC item–BMI (kg/m2), which
indicates the self-reported BMI by the participant, had significant association with baseline BCAA levels,
showing that participants with higher BMI had significantly higher concentrations of BCAA at baseline
(p ≤ 0.001, Table S1). Regarding RBP4 levels, only FINDRISC item–blood pressure medication showed
a significant relationship. Those participants who reported taking blood pressure medication had
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significantly higher levels of RBP4 than subjects who did not report taking blood pressure medication
(p < 0.001, Table S1).
Figure 3. Association between baseline FINDRISC and baseline BCAA and RBP4 levels. BCAA:
branched amino acid. RBP4: retinol-binding protein 4. The p-value, which compares baseline
FINDRISC according to baseline BCAA quartiles (A) or baseline RBP4 quartiles (B), was calculated by
ANOVA test.
3.3. Clinical, Anthropometric, Biochemical, and Lifestyle Parameters across the Study
The evolution of biochemical and anthropometric characteristics of all Spanish subjects who
completed the Feel4Diabetes study are shown in Table 3, according to randomized grouping. Both
control and intervention groups showed a significant decrease in body weight in Follow-up 1, but
no significant decrease in Follow-up 2 compared to the baseline, with no difference between groups.
Only the intervention group showed a statistically significant decrease in BMI after one year of study
compared to baseline. Regarding lipid profiles, the control group showed a significant decrease in TG
and HDLc levels during the first year of the study. Besides, the TG levels also continued to decrease
during the second year in the control group. The intervention group did not show any significant
decline of TG, but they showed a significant increase in HDLc concentrations, which could be explained
by the rise of physical activity in this group. Concerning glycemic parameters, only the control group
had a significant increase in their glucose levels at Follow-up 1, while the intervention group did not
have a significant change in their glucose concentration. Interestingly, HbA1c significantly dropped
in both groups, although the decrease in the intervention group was significantly higher than in the
control group throughout the follow-up (p = 0.011, comparing both groups).
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Table 3. Evolution of biochemical and anthropometric characteristics of all Spanish control and intervention subjects who have completed the Feel4Diabetes study.
Control Group (N = 115) Intervention Group (N = 151)
Overall p2016
(N = 115)
2017
(N = 115)
2018
(N = 115)
2016
(N = 151)
2017
(N = 151)
2018
(N = 151)
Men, n (%) 39 (33.9%) 39 (33.9%) 39 (33.9%) 51 (33.5%) 51 (33.5%) 51 (33.5%) 0.682
Body weight, kg 78.7 ± 17.5 77.5 ± 16.0 * 77.9 ± 16.4 80.1 ± 17.1 79.2 ± 16.7 * 79.5 ± 16.8 0.638
BMI, kg/m2 28.5 ± 5.75 28.3 ± 5.71 28.4 ± 5.77 28.9 ± 5.20 28.3 ± 5.23 * 28.5 ± 5.21 0.703
Total cholesterol, mg/dL 202 ± 34.6 198 ± 35.1 196 ± 37.3 198 ± 34.6 196 ± 34.2 199 ± 34.1 0.068
LDL cholesterol, mg/dL 127 ± 29.7 122 ± 30.8 124 ± 34.5 124 ± 29.4 120 ± 27.8 124 ± 28.2 0.344
Triglycerides, mg/dL 88.0 (31.0–118) 78.0 (61.0–111) * 81.0 (57.5–119) ** 80.0 (63.0–119) 79.0 (60.5–116) 84.0 (63.0–113) 0.542
HDL cholesterol, mg/dL 54.6 ± 12.7 56.4 ± 13.0* 54.6 ± 11.4 53.7 ± 11.1 56.4 ± 11.5* 55.1 ± 11.8 ** 0.089
Apolipoprotein A, mg/dL 169 ± 32.5 167 ± 28.6 144 ± 21.2 ** 167 ± 24.6 172 ± 25.8* 145 ± 20.0 ** 0.334
Apolipoprotein B, mg/dL 96.9 ± 23.9 95.8 ± 21.9 88.1 ± 24.0 ** 95.9 ± 25.9 94.9 ± 24.8 88.5 ± 21.1 ** 0.264
Glucose, mg/dL 92.4 ± 18.1 95.6 ± 33.8 * 92.6 ± 18.0 91.9 ± 15.4 93.0 ± 15.1 90.6 ± 11.7 0.417
HbA1c, % 5.53 ± 0.75 5.46 ± 0.81 * 5.36 ± 0.33 ** 5.51 ± 0.44 5.40 ± 0.53* 5.36 ± 0.36 ** 0.011
GGT, U/L 27.3± 20.5 27.0 ± 21.1 28.1 ± 26.4 27.1 ± 26.1 27.5 ± 25.0 26.3 ± 21.7 0.271
GOT, U/L 20.8± 7.63 21.8 ± 8.81 21.6 ± 8.81 21.3 ± 6.60 22.7 ± 9.45 21.4 ± 4.94 0.489
GPT, U/L 22.0 ± 14.9 22.4 ± 17.5 22.4 ± 17.5 20.3 ± 11.5 22.3 ± 15.2 22.3 ± 15.2 0.332
BCAA, nmol/nL 406 ± 105 400 ± 108 402 ± 103 411 ± 113 395 ± 86.8* 363 ± 80.5 ** <0.001
RBP4, ng/mL 7.09 ± 5.18 7.09 ±5.27 6.87 ± 5.09 7.57 ± 5.12 7.42 ± 4.83 7.76 ± 5.31 0.523
Physical activity, steps/day 4637 ± 2885 5544 ± 3433 6127 ± 3808 5601 ± 1834 5851 ± 2349 7208 ± 2543 0.273
BMI: body mass index. LDL: low density lipoprotein. HDL: high density lipoprotein. HOMA: homeostatic model assessment. GGT: gamma-glutamyl transferase. GOT: glutamic
oxaloacetic transaminase. GPT: glutamic-pyruvate-transaminase. HbA1c: glycated hemoglobin. BCAA: branched chain amino acid. RBP4: retinol-binding protein 4. Physical activity was
measured as the total steps per day. Quantitative variables are expressed as means ± standard deviations except for variables not following normal distribution that are expressed as
medians (interquartile ranges). Overall p was calculated by mixed lineal model comparing the variation during the time in control vs. intervention group. * Denotes significant difference
between baseline year (2016) and the first year to intervention (2017) in each group calculated by t-test or U Mann–Whitney as appropriate. ** Denotes significant difference between
baseline year (2016) and the second year to intervention (2018) in each group calculated by t-test or U Mann–Whitney as appropriate.
Cells 2020, 9, 693 10 of 19
Especially interesting is the significant decline in BCAA concentration in those subjects in the
intervention group compared with the control group throughout the follow-up (p < 0.001 between both
groups). BCAA concentration change followed a linear decrease in the intervention group, getting
lower concentrations at the end of the follow-up. However, RBP4 variation did not show significant
variation in any group. Baseline RBP4 levels were slightly higher in the intervention group than in the
control group, although no significant differences were observed between groups. These differences
remained throughout the study and even increased a little at the end of the study, but always remained
insignificant (p = 0.523, Figure 4).
Figure 4. BCAA and RBP4 variation over time, depending on the group. BCAA: branched amino acid.
RBP4: retinol-binding protein 4. The p-value, which compares BCAA variation (A) or RBP4 variation
(B) over time depending on the group, was calculated by ANOVA test.
Due to the marked decrease in BCAA concentrations in the intervention group, we studied the
relation between BCAA and RBP4 variations with anthropometrics, glucose metabolism, and lifestyle
parameters throughout the study. Only physical activity had any relationship with BCAA and RBP4
variations, showing that participants who increased their physical activity had a higher drop of BCAA
and RBP4 concentrations (p < 0.001, Table 4). When we analyzed the correlation between BCAA and
RBP4 variation with diabetes markers depending on the group the subjects were allocated to, the
glucose variation showed a significant relationship with BCAA variation only in the intervention
group. Participants who had higher glucose decreases had the greatest BCAA rise (r = −0.10, p = 0.025).
Nevertheless, regression analysis continued to show an association between glucose variation and
BCAA variation throughout the follow-up study (3.731 × 10−2 (−0.1967 to 0.2714), p = 0.754). BCAA
variation did not show any association with any glucose metabolism parameter in the control group
(Figure 5A). Neither glycemic parameter change showed a significant relationship with the RBP4
variation in either the intervention or control groups (Figure 5B).
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Table 4. Relationship between BCAA variation and RBP4 variation with variation of anthropometric, diabetic markers, dietary markers, and physical exercise
parameters throughout the Feel4Diabetes study (2016–2018).
BCAA Variation p p1
RBP4 Variation p p1
Q1 (N = 67) Q2 (N = 66) Q3 (N = 65) Q4 (N = 68) Q1 (N = 66) Q2 (N = 66) Q3 (N = 66) Q4 (N = 68)
BCAA variation, % −28.3 ± 9.03 −10.8 ± 3.79 −0.42 ± 3.16 18.8 ± 12.4 <0.001 <0.001 −2.13 ± 20.4 −4.17 ± 18.4 −9.11 ± 18.2 −5.35 ± 18.5 0.194 0.343
RBP4 variation, % 22.8 ± 80.7 8.98 ± 55.7 15.4 ± 75.4 13.2 ± 60.6 0.706 0.440 −41.5 ± 14.6 −11.0 ± 6.62 16.7 ± 9.33 96.2 ± 90.0 <0.001 <0.001
BMI variation, % −0.79 ± 7.43 −1.73 ± 8.37 0.34 ± 6.33 0.58 ± 5.33 0.201 0.224 −0.60 ± 6.54 −0.50 ± 6.11 −0.36 ± 7.56 −0.16 ± 7.68 0.987 0.731
Body weight
variation, % −0.67 ± 7.58 −1.37 ± 8.29 0.56 ± 5.12 0.63 ± 5.74 0.260 0.263 −0.27 ± 6.68 −0.33 ± 6.15 −0.13 ± 7.71 −0.11 ± 6.82 0.997 0.894
Glucose variation, % 0.25 ± 9.46 −1.43 ± 11.2 0.20 ± 9.15 0.71 ± 9.86 0.624 0.785 −0.63 ± 8.26 0.70 ± 9.98 1.11 ± 10.2 −1.38 ± 11.1 0.437 0.654
Hb1Ac variation, % −1.33 ± 5.62 −2.74 ± 3.41 −1.65 ± 3.84 −1.84 ± 3.56 0.263 0.537 −1.79 ± 3.78 −1.68 ± 2.98 −1.41 ± 5.77 −2.63 ± 3.87 0.379 0.209
Vegetables variation
consumption
(g/week), %
55.2 ± 179 52.5 ± 182 35.7 ± 166 55.3 ± 176 0.919 0.995 45.4 ± 172 67.5 ± 227 37.7 ± 160 47.2 ± 127 0.825 0.951
Legume variation
consumption
(g/week), %
49.3 ± 114 24.1 ± 105 88.6 ± 218 52.4 ± 144 0.216 0.907 46.2 ± 125 39.6 ± 149 39.0 ± 97.4 91.4 ± 216 0.292 0.227
Read meat variation
consumption
(g/week), %
2.21 ± 72.6 -20.0 ± 62.3 52.3 ± 149 4.76 ± 73.4 0.002 0.862 10.4 ± 110 10.4 ± 75.4 10.7 ± 94.4 14.6 ± 121 0.996 0.856
Fish variation
consumption
(g/week), %
14.5 ± 72.1 -2.88 ± 65.5 25.7 ± 123 39.4 ± 96.0 0.133 0.145 18.1 ± 69.2 23.0 ± 117 19.8 ± 97.8 19.7 ± 90.0 0.995 0.919
Physical activity
variation (number
steps/day), %
48.5 ± 64.9 14.9 ± 43.3 50.7 ± 65.6 −18.9 ± 45.5 0.537 0.001 58.7 ± 78.9 18.7 ± 28.9 7.44 ± 41.2 18.0 ± 59.7 0.696 <0.001
BMI: body mass index. HbA1c: glycated hemoglobin. BCAA: branched amino acid. Physical activity was measured as the total steps per day. RBP4: retinol-binding protein 4. Quantitative
variables are expressed as means ± standard deviations. 2 p refers to differences among all quartiles in each study group and was calculated by ANOVA or Kruskall–Wallis, as applicable. 3
p refers to differences comparing Q1 and Q4 quartiles in each study group and was calculated by t-test or U Mann–Whitney, as applicable.
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Figure 5. Correlation between BCAA (A) or RBP4 (B) variation with diabetes markers depending on
the group. BCAA: branched amino acid. RBP4: retinol-binding protein 4. BMI: body mass index.
HbA1c: glycated hemoglobin. ∆, %: variation expressed as percentage. The variation was calculated
comparing the concentration at Follow-up 2 (2018) to baseline levels (2016). Correlation analyzed was
performed by Pearson’s tests. * Denotes significant difference with p < 0.05.
Finally, due to the close relationship between BCAA and RBP4 levels and body weight [22–24],
we studied RBP4 and BCAA variations according to bodyweight percentage change. We considered it
a clinically significant weight loss when 5% of bodyweight reduction, according to ADA guidelines
recommendations in overweight and obesity management in patients with prediabetes and T2D [25],
was achieved. BCAA variation showed a positive relationship with body weight change. These effects
were observed in both groups, although a much greater decrease was observed in subjects within
the intervention group. However, the wide standard deviation should be taken into account when
interpreting the findings (Table 5).
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Table 5. Relationship between BCAA and RBP4 variations according to weight change experienced during the study in each group.
Control Group
p2
Intervention Group
p2
Subjects who Have
Lost more than 5%
of Weight
throughout the
F4D Study
(N = 19)
Subjects who Have
Varied less than 5%
of Weight
throughout the
F4D Study
(N = 78)
Subjects who Have
Gained more than
5% of Weight
throughout the
F4D Study
(N = 17)
Subjects who Have
Lost more than 5%
of Weight
throughout the
F4D Study
(N = 21)
Subjects who Have
Varied less than 5%
of Weight
throughout the
F4D Study
(N = 103)
Subjects who Have
Gained more than
5% of Weight
throughout the
F4D Study
(N = 24)
BCAA variation, % −1.48 ± 17.2 −0.11 ± 19.9 5.58 ± 16.8 0.493 −10.9 ± 28.6 −9.55 ± 15.3 −7.14 ± 17.3 0.768
RBP4 variation, % 16.8 ± 73.4 10.9 ± 54.0 9.27 ± 36.3 0.904 44.2 ± 129 13.1 ± 51.8 24.2 ± 104 0.232
BCAA: branched chain amino acid; RBP4: retinol binding protein 4. Variables are expressed as means ± standard deviations. p2 refers to differences among the three groups in each study
group and was calculated by ANOVA or Kruskall–Wallis, as applicable.
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4. Discussion
The main findings of the study include (1) BCAA concentrations directly correlated to FINDRISC
score and glucose impairment (both glucose, HbA1c, insulin, and HOMA–IR) at baseline in subjects
with a high-risk of developing T2D; (2) BCAA levels decreased across the study in those participants
receiving the school- and community-based intervention; (3) the improvement in BCAA concentration
in these subjects occurred regardless of weight loss, although a higher decrease of its levels was
observed in subjects reaching higher weight loss; (4) RBP4 was not significantly associated to glucose
metabolism and body weight at baseline, and its concentration did not significantly vary across the
study in any group.
BCAA has increasingly been studied as playing a role in diabetes, and previous research has
demonstrated that higher concentrations of these amino acids are related to insulin resistance and are
predictive of T2D developing in nondiabetic subjects [6,7,9,26].
Our results are in accordance with previous research by finding that baseline BCAA concentrations
are directly correlated to glucose, HbA1c, and insulin resistance, assessed by HOMA–IR, in subjects
with a high risk of developing T2D. The association was statistically significant in both the participants
with prediabetes, T2D, and normoglycemic status. Notably, our results revealed that the FINDRISC
score was directly associated with BCAA concentration at baseline. Those participants who had a
higher score showed greater levels of these amino acids at the beginning of the study. Thus, our
findings point out that this questionnaire would not just be a good predictor for T2D incidence in the
next 10 years but would reflect the early stages of disease pathogenesis.
In previous literature, whether lifestyle intervention could modify BCAA concentrations has
barely been explored, and heterogeneous results have been revealed. In the PREDIMED trial, it
was demonstrated that a Mediterranean diet rich in extra-virgin olive oil significantly decreased the
levels of BCAA and attenuated the positive association between plasma BCAA concentration and T2D
incidence [27]. Zheng Y et al. reported significant reductions in BCAA levels both in the POUNDS LOST
(Preventing Overweight Using Novel Dietary Strategies Trial) and the DIRECT (Dietary Intervention
Randomized Controlled Trial) studies [28]. However, a recent study exploring the effect of a low-calorie
diet with standard protein content (0.8 g/kg/day) or a high-protein content (1.2 g/kg/day) showed
no statistically significant changes in BCAA concentrations despite a −6.2% and −7.2% weight loss
after interventions were reached in each diet group, respectively [29]. Even though other research
previously described greater levels of BCAA in subjects who were overweight or obese, the association
between weight loss and BCAA change differs among studies [30–32]. In both the POUNDS LOST and
in the DIRECT trials, weight loss was directly related to the reduction of BCAA by describing a ∼0.6
µmol/L decrease in log tyrosine per kilogram of weight loss [28]. The PREDIMED study found that
elevated plasma levels of BCAA were associated with higher T2D regardless of weight loss, although
the association of these amino acids, concentration, and body weight change was not shown [27]. Our
study is the first one describing the effect of a school- and community-based intervention, focused not
on weight loss but on the improvement of dietary and physical activity habits on BCAA concentrations
in individuals with a high risk of developing T2D. These small differences between the control and
intervention groups throughout the follow-up could be explained, on one hand, by the study design,
which did not seek the weight loss of the participants, but the improvement of their dietary habits
and physical exercise. On the other hand, in this study, we included all Spanish participants who
attended the three study visits by involving an 18.6% drop-out rate, which was especially high during
the first year. This relatively high drop-out is quite common within community-based intervention
studies, especially when developing in vulnerable populations. However, this is an important issue
that would be necessary to consider when interpreting the main outcomes of the study. Our findings
demonstrate that this intervention led to a significant reduction in these amino acid levels despite the
participants scarcely varying their body weight. We did not find a significant correlation between
weight loss and change in BCAA levels across the study, and those participants receiving intervention
showed statistically significant reductions in these metabolites regardless of weight loss. However,
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it is important to note that the subjects who reached >5%-weight loss showed a higher decrease in
BCAA levels than those who gained body weight or subjects who had <5%-weight loss, although no
significant differences were founded. Our results demonstrate that a decrease in BCAA concentrations
can be reached with cost-effective community-based interventions focused on healthy lifestyles beyond
weight loss.
The mechanisms linking BCAA concentrations and glucose metabolism and T2D are not fully
understood, and it is rarely even discussed if elevated concentrations of these amino acids could be
a cause or a consequence of insulin resistance. High levels of insulin have been demonstrated to
cause impaired function of branched-chain aminotransferase (BCAT) and branched-chain keto acid
dehydrogenase (BCKDH), which are enzymes with a key role in BCAA metabolism, and subjects with
T2D show decreased skeletal muscle BCAT and BCKDH expression [33,34]. This impairment leads to
the accumulation of branched-chain keto acids and metabolites such as diacylglycerol and ceramide,
which potentially contribute to the development of further insulin resistance. Another hypothesis
includes the mammalian target of rapamycin complex 1 (mTORC1), which is activated by BCAA but
also by insulin and glucose via cellular ATP availability. BCAA overload may cause insulin resistance
by the activation of mTOR signaling, resulting in persistent IRS-1 phosphorylation by mTORC1
and inhibition of insulin signaling [10,35]. A recent study has demonstrated that brown adipose
tissue actively utilizes BCAA in the mitochondria for thermogenesis and promotes systemic BCAA
clearance [12]. Our study findings, like in the PREDIMED trial, point out that BCAA concentrations
decrease after lifestyle intervention regardless of body weight. So distinct, yet non-mutually exclusive
mechanisms would be expected to be responsible for the physiological effects described for these
amino acids.
RBP4 is an adipokine that has been implicated in the pathophysiology of insulin resistance
through immunity, inflammatory, and GLUT4 regulation mechanisms in adipose and vascular
tissues [14,15,36–38]. Several studies have demonstrated that a low-calorie diet considerably decreases
RBP4 levels and that effect is dependent on the amount of weight loss [16,39]. A few studies have found
that lifestyle intervention causes a decrease in RBP4 concentrations regardless of weight loss [40,41]. In
our study, we did not find a significant variation of RBP4 levels after study intervention, and neither an
association between RBP4 nor body weight was shown. The Feel4Diabetes trial intervention was not
focused on weight loss but on the improvement of dietary and physical habits. The participants of our
trial reached a ~1% of weight loss, which would be insufficient to lead to RBP4 changes according to
previous researches. We did not find a significant association between RBP4 concentration and glucose
metabolism parameters at baseline, and no association between glucose and HbA1c changes and RBP4
variation across the study was observed. The participants of our study were mostly normoglycemic,
which could have played an essential role in the lack of association between RBP4 and glucose
homeostasis, which is mainly described in subjects with glucose impairment.
Our study has several limitations worth mentioning. Firstly, dietary assessment methodology
did not allow us to quantify both energy and different nutrients intake that would be of interest to
know if some specific dietary characteristics could impact in the change of both in BCAA and RBP4
concentrations. On the other hand, the dropout rate of the study was relatively high, which could
limit the findings of the study. However, this issue is common in long-term epidemiological and
interventional studies, especially those developed in vulnerable groups of subjects.
In conclusion, our findings reveal that BCAA levels were directly related to the FINDRISC score
and glucose impairment in subjects with a high-risk of developing T2D. In addition, our study shows
that school- and community-based interventions focused on lifestyle improvement could lead to an
improvement in BCAA concentrations regardless of weight loss. Therefore, we hypothesize that the
decrease of BCAA levels could be explained by the combination of lifestyle changes and a small decrease
in body weight. We did not find a significant association between RBP4 concentrations and glucose
metabolism or body weight in study participants at baseline and, moreover, the intervention did not
significantly influence RBP4 levels. According to our results, we believe that two main issues should be
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highlighted. Firstly, FINDRISC should be predictive of a high risk of developing T2D, including early
stages of disease pathogenesis. Secondly, a community-based intervention has demonstrated to lead
to a decrease in BCAA concentrations, of which high concentrations have been previously related to
TDM2 development. Therefore, to prevent or delay the onset of T2D by identifying those individuals
at high risk and finding optimal approaches to reach this goal should be a priority for both the political
and scientific communities.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/9/3/693/s1.
Table S1. Baseline BCAA and RBP4 levels according to FINDRISCK items. Figure S1. Flow chart. Figure S2. BCAA
concentration evolution according to sex in both groups. BCAA: branched amino acid. Quantitative variables are
expressed as means ± standard deviations. The p1 compared the evolution of biochemical and anthropometric
characteristics along to follow-up. The p2 compared baseline BCAA concentrations according to sex groups. The
p-value was calculated by ANOVA or Student’s test, as appropriate. Figure S3. Correlation between baseline
levels of BCAA and RBP4 with clinical parameters (N = 266). BCAA: branched amino acid. TG: triglycerides.
HDLc: high density lipoprotein cholesterol. LDLc: low density lipoprotein cholesterol. GGT: gamma-glutamyl
transferase. GOT: glutamic oxaloacetic transaminase. GPT: glutamic-pyruvate-transaminase. SBP: systolic blood
pressure. DBP: diastolic blood pressure. RBP4: retinol-binding protein 4. Correlation analyzed was performed by
Pearson’s tests. * Denotes significant difference with p < 0.05.
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